Events Annual Scientific Meeting Past Programs SIO2024 Program

SIO2024 Program

Friday, 26 January 2024
7:45 a.m. - 8:30 a.m.

Breakfast and Industry Symposium presented by Boston Scientific

Cryoablation for Painful Bone Metastases: From Clinical Studies to FDA Approval to Patient Impact

  • Scott Genshaft, MD, UCLA Health
  • Rahul Sheth, MD, University of Texas MD Anderson Cancer Center
8:45 a.m. - 10:00 a.m.

President's Welcome & Dr. Sidney Wallace and Dr. Michael J. Wallace Distinguished Lecture

  • President's Welcome, Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
  • Program Chair's Program Overview, Vijay Ramalingam, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
  • Wallace Lecture Laudation, William Rilling, MD, FSIR, Medical College of Wisconsin
  • Dr. Sidney Wallace and Dr. Michael J. Wallace Distinguished Lecture, "Research in Interventional Oncology", Prof. Thierry de Baere, MD, Gustave Roussy Cancer Center
10:30 a.m. - 11:30 a.m.

State-of-the-Art HCC

Moderators: Laura Crocetti, MD, PhD, EBIR, University of Pisa; Parissa Tabrizian, MD, MSc, FACS, Mount Sinai Medical Center

  • Standard of Care Systemic Therapies and Pivotal Trials, Adam Burgoyne, MD, PhD, UC San Diego
  • Barcelona Update and BCLC Stage Migration Issues, David C. Madoff, MD, Yale School of Medicine
  • 2024 Resection and Transplantation Updates, Parissa Tabrizian, MD, MSc, FACS, Mount Sinai Medical Center
  • Current Status: Locoregional Primer, Laura Crocetti, MD, PhD, EBIR, University of Pisa
11:30 a.m. - 12:45 p.m.

Expo Hall Open
 

Lunch and Industry Symposium presented by BD

Novel Power Driven Bone Biopsy Technologies and Techniques for Routine and Complex Procedures

  • Jay Acharya, MD, Keck Medicine of USC
  • Benjamin Levin, MD, UCLA
 

Lunch and Industry Symposium presented by Boston Scientific

TheraSphere Y90: Revving up "RPM" and Accelerating the Future of Combination Therapy

  • Tyler Sandow, MD, Ochsner Health
  • Lingling Du, MD, Ochsner Medical Center
12:45 p.m. - 2:15 p.m.

Lung Cancer and Lung Mets Tumor Board

Moderators: Robert Suh, MD, David Geffen School of Medicine at UCLA; Damian E. Dupuy, MD, FACR, Cape Cod Health Care

  • Clinical Trials and Patient Selection in Lung Cancer Ablation: Where Does IR Stand? Alda Tam, MD, MD Anderson Cancer Center
  • Ablation and SBRT in Lung Cancer: How Do We Decide? Florian J. Fintelmann, MD, Massachussetts General Hospital
  • Screening and Treatment of Small Lesions, Damian E. Dupuy, MD, FACR, Cape Cod Health Care
  • Techniques and Approaches to Complicated Lesions, Robert Short, MD, PhD, Dayton VAMC/WSU BSOM
  • State-of-the-Art Endobronchial Techniques for Lung Cancer Staging and Treatment,  Michael Pritchett, DO, MPH, FirstHealth of the Carolinas
  • Lung Mets Tumor Board, All above faculty; Jae Y. Kim, MD, City of Hope Medical Group; Percy Lee, MD, FASTRO, City of Hope National Medical Center/Orange County and Coastal Radiation Oncology

Neuroendocrine and NET Tumor Board

Moderators: Nicholas Fidelman, MD, University of California San Francisco; Michael Soulen, MD, University of Pennsylvania

  • Emerging Medical and Surgical Approaches for NET Liver Metastases: 2024 Update, Emily Bergsland, MD, University of California San Francisco
  • State-of-the-Art PRRT: Which Patients Should Get PRRT and Which Should Get Emblotherapy? Ghassan El-Haddad, MD, H. Lee Moffitt Cancer Center and Research Institute
  • TACE, TAE, TARE: Which Therapy is Indicated? Nicholas Fidelman, MD, University of California San Francisco
  • Therapy Selection for Progressive Low Volume Liver and Extrahepatic Disease, Jaydira Del Rivero, MD, National Cancer Institute/National Institutes of Health
  • Pre- and Post-Procedure Care in Neuroendocrine Tumors: Practical Tips to Avoid Complications During LRTB, Michael Soulen, MD, University of Pennsylvania
  • NET Tumor Board, All above faculty

Ablation Hands-on: Image Guidance & Robotics

Moderators: Bruno C. Odisio, MD, PhD, FSIR, The University of MD Anderson Cancer Center; Marie Beermann, MD, Danderyd Hospital

  • Rationale Behind Using Image Guidance and Advanced Ablation, Denis Szejnfeld, MD, PhD, Unifesp
  • Basics of Stereotactic Ablation and Setting Up a Program, Iwan Paolucci, PhD, MD Anderson Cancer Center
  • Stereotactic RF Ablation of the Liver: Why I Use It and the Advantages of Multiple Needles, Bruno C. Odisio, MD, PhD, FSIR, The University of MD Anderson Cancer Center
  • Stereotactic Microwave Ablation of Liver Lesions, Marie Beermann, MD, Danderyd Hospital
  • Putting it All Together: Treatment Planning, Guidance, and Ablation, Bruno C. Odisio, MD, PhD, FSIR, The University of MD Anderson Cancer Center
  • Hands-on Learning, All above faculty
2:30 p.m. - 3:30 p.m.

AI

Moderators: Aaron Abajian, MD; Judy Gichoya Wawira, MS, PhD, Emory University

  • AI for Dummies: Everything You're Too Embarrassed to Ask, Joseph Erinjeri, MD, PhD, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College
  • Augmenting IR Imaging with Artificial Intelligence, Jarrel Chen Yi Seah, MBBS, BMedSci(Hons), Harrison.ai/Radiology Registrar at Alfred Health
  • Practical and Ethical Challenges with Artificial Intelligence, Judy Gichoya Wawira, MS, PhD, Emory University
  • AI in HCC Therapy: Treatment Planning and Response Assessment, Aaron Abajian, MD

SIO Grant Showcase

Moderator: Julius Chapiro, MD, PhD, Yale School of Medicine

  • SIO Grants Overview, Julius Chapiro, MD, PhD, Yale School of Medicine
  • 2022 Grant Update: Single Cell Analysis of Combined Thermal Ablation and Immunotherapy of HCC, Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center
  • 2022 Grant Update: Stoking an Anti-Liver Cancer Immune Response with Cryoablation Plus Intratumoral Immunostimulant, Isabel Gala Newton, MD, PhD, UCSD Health and VA San Diego Healthcare System
  • 2022 Grant Update: Immunobiologic and Metabolic Determinants of Response to Combination Locoregional and Immunotherapy in HCC, Kelley Weinfurtner, MD, University of Pennsylvania
  • 2022 Grant Update: Engineered Extracellular Vesicles to Modulate Immunotherapy in Liver Cancer, Kiyoyuki Minamiguchi, MD, PhD, MD Anderson Cancer Center
  • 2023 Grant Update: Spatial proteogenomics for prediction of response in combined radioembolization and immunotherapy of HCC, Elif Öcal, MD, LMU University Hospital Munich
  • 2023 Grant Update: Understanding the Influence of Hepatocellular Carcinoma Tumor Immune Microenvironment on Response to Y-90 Radioembolization and Potential Combinations with Immune Checkpoint Inhibition, Christopher D. Malone, MD, Mallinckrodt Institute of Radiology at Washington University School of Medicine

Y90 Glass

Moderators: Edward Kim, MD, FSIR, Mount Sinai Health Systems; Riad Salem, MD, MBA, Northwestern University

  • Systemic Therapies and Y90, Nora Tabori, MD, Medstar Health
  • Why Rad Seg is Curative, Kirema Garcia-Reyes, MD, Icahn School of Medicine at Mount Sinai
  • Specific Activity and Does Dose Matter, Christopher D. Malone, MD, Mallinckrodt Institute of Radiology at Washington University School of Medicine
  • Why Y90 for PVT is Still Relevant, Robert Lewandowski, MD, FSIR, Northwestern University
  • Consolidative Y90 Techniques for Large HCC, Jin Woo Choi, MD, PhD, Seoul National University Hospital
3:30 p.m. - 5:00 p.m.

Expo Hall and Discovery Theatre

  • Discovery Theatre Poster Presentations
    • Histotripsy Bubble Cloud Localization on Cone-Beam CT in an Ex Vivo Phantom and an In Vivo Porcine Liver Model, Katrina Falk, University of Wisconsin, Madison
    • Radiogenomics of Colorectal Cancer Liver Metastases Intended for Y90 Therapy Identifies KRAS Heterogeneity, Ahmed Al-Khafaji, MD, Emory University Healthcare
    • HeatSYNCTM Gel: Mechanism of Action as Thermal Accelerant and Development of Drug-Eluting System for Anti-tumor Agents Post-Ablation, William Park, MD, Rhode Island Hospital
  • Discovery Theatre presented by ABK Biomedical
  • Discovery Theatre presented by Varian, a Siemens Healthineers Company
5:00 p.m. - 6:00 p.m.

HCC Tumor Board

Moderators: Riad Salem, MD, MBA, Northwestern University; Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School

Faculty: Roberto Iezzi, MD, FCIRSE; Laura Crocetti, MD, PhD, EBIR, University of Pisa; Parissa Tabrizian, MD, MSc, FACS, Mount Sinai Medical Center; Terrence Williams, MD, City of Hope Medical Group; Adam Burgoyne, MD, PhD, UC San Diego; Sammy Saab, MD, UCLA
6:00 p.m. - 7:30 p.m.

Science and Industry Welcome Reception

All attendees are invited to join us to celebrate the start of the 2024 Annual Meeting. This networking reception will include poster and award presentations in the Exhibit Hall.
Saturday, 27 January 2024
7:45 a.m. - 8:30 a.m.

Breakfast and Industry Symposium presented by TriSalus Life Sciences

Seeking to Enable Immunotherapy for Liver and Pancreatic Tumors: Updates from PERIO Trials

  • Intratumoral Pressure: A Barrier to Drug Delivery, Alexander Kim, MD, TriSalus Life Sciences
  • Immunosuppression and Novel Treatment Approaches, Steven C. Katz, MD, FACS, TriSalus Life Sciences/Brown University School of Medicine
  • The PERIO-01 and -02 Trials: Enabling Immunotherapy for Uveal Melanoma Liver Metastases and Primary Liver Cancers, Rahul Sheth, MD, MD Anderson Cancer Center
 

Breakfast and CME Session: Synergizing for Success in HCC: Immuotherapy Advances and the Role of the Interventional Radiologist-Oncologist Collaboration Across the Disease Continuum

Presented by PeerView Institute for Medical Education

  • Preconsult Prep: Establishing the Alliance in HCC—The Importance of IR/Oncologist Collaboration for Addressing Challenges and Unmet Needs in HCC, Lipika Goyal, MD, Stanford Medicine
  • Clinical Consult Session 1:  Partnership at the Initial Stages of Disease: Updates in Immunotherapy and LRT Options in Early- and Intermediate-Stage HCC, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University
  • Clinical Consult Session 2:   Coordinating Care at Disease Progression: Ensuring a Smooth Transition When Integrating Systemic Therapy in Advanced-Stage HCC, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University
  • Summary and Q&A, Lipika Goyal, MD, Stanford Medicine; Riad Salem, MD, MBA, Northwestern University
8:45 a.m. - 10:15 a.m.

IO Essentials: Solid Tumor Interventions

Moderators: Christos Georgiades, MD, PhD, Johns Hopkins University; Nishita Kothary, MD, FSIR, Stanford School of Medicine

  • Physics of Ablation Modalities, Christos Georgiades, MD, PhD, Johns Hopkins University
  • Liver: Introduction to Ablation and Guidelines Overview, Nishita Kothary, MD, FSIR, Stanford School of Medicine
  • Lung: Introduction to Ablation and Guidelines Overview, Stephen Hunt, MTR, MD, PhD, FSIR, University of Pennsylvania
  • RCC: Introduction to Ablation and Guidelines Overview, Erica Alexander, MD, Memorial Sloan Kettering Cancer Center
  • Radioembolization: Getting Started in Y90, Juan Gimenez, MD, Ochsner Health
  • Intro to TACE and Patient Management, Zach Berman, MD, UC San Diego
  • Pain Management Techniques and IO, Rahul Sheth, MD, MD Anderson Cancer Center
9:00 a.m. - 10:00 a.m.

Intra- and Extrahepatic Biliary

Moderators: William Rilling, MD, FSIR, Medical College of Wisconsin; Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School

  • Actionable Mutations and Systemic Therapy Update, Richard S. Finn, MD, Geffen School of Medicine at UCLA
  • Surgical Considerations for Intrahepatic Cholangiocarcinoma, Laleh Melstrom, MD, MSCI, City of Hope
  • Combination Therapy for Intrahepatic Disease, William Rilling, MD, FSIR, Medical College of Wisconsin
  • Endobiliary Therapies for Extrahepatic Disease, Kaiwen Huang, MD, MS, PhD, National Taiwan University
  • Post-Surgical Biliary Disasters: M&M, Prof. Adam Hatzidakis, MD, AHEPA University Hospital of Thessaloniki/Aristotle Medical School
 

Will TACE Survive the Age of Radioembolization and Immunotherapy?

This is a debate-style session.

Moderator: Sarah White, MD, MS, Medical College of Wisconsin

  • Pro-TARE, Riad Salem, MD, MBA, Northwestern University
  • Pro-cTACE, Michael Soulen, MD University of Pennsylvania
  • Pro-Immunotherapy, Rony Avritscher, MD, University of Texas MD Anderson Cancer Center
10:30 a.m. - 11:30 a.m.

Scientific Oral Abstracts

Moderators: Nicholas Fidelman, MD, University of California San Francisco; Rony Avrischer, MD, University of Texas MD Anderson Cancer Center

  • Four-year overall survival update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, Farshid Dayyani, MD, PhD, University of California, Irvine
  • Initial efficacy and safety of RP1 plus nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study, Bartosz Chmielowski, MD, University of California Los Angeles
  • EMERALD-1: a Phase 3, randomized, placebo-controlled study of transarterial chemoembolization (TACE) combined with durvalumab (D) with or without bevacizumab (B) in participants with unresectable hepatocellular carcinoma (uHCC) eligible for embolization, Joe Erinjeri, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Embolic protection and thrombosis risk of inferior vena cava filters in cancer patients: a single center, retrospective study, Koustav Pal, The University of Texas MD Anderson Cancer Center
  • Ultrasound-guided thermal ablation of cervical metastases from thyroid carcinoma, Ricardo Miguel Costa de Freitas, MD, PhD, Instituto do Cancer do Estao de Sao Paulo (HCFMUSP)
  • Sarcopenia and Myosteatosis are Associated with Worse Survival after TACE of Liver Metastases, Fereshteh Yazdanoanah, MD, HMBA, University of Pennsylvania
  • Factors impacting survival after transarterial radioembolization in patients with intrahepatic cholangiocarcinoma: A combined analysis of the prospective CIRT and CIRT-FR studies, Nathalie Kaufmann, MBA, CIRSE
11:30 a.m. - 12:45 p.m.

Expo Hall Open
 

Lunch and Industry Symposium presented by Sirtex Medical

Optimizing Y90 Treatment Logistics with SIR-Spheres Order-Map-Treat and FLEXdose Delivery Programs  

  • Robert Grammer, MD, West Virginia University
 

Lunch and Industry Symposium presented by Guerbet

Leveraging the Benefits of Lipiodol Imaging in HCC Management

  • Julius Chapiro, MD, PhD, Yale School of Medicine
  • Marcelo Guimaraes, MD, MBA, FSIR, Medical University of South Carolina (MUSC)
  • Ziga Cizman, MD, MPH, University of Utah
12:45 p.m. - 1:45 p.m.

Renal/GU

Moderators: David Breen, MD, MRCP, FRCR, University Hospitals Southampton; Rodrigo Gobbo, MD, PhD, Hospital Israelita Albert Einstein

  • T1A and Current Guidelines, Rodrigo Gobbo, MD, PhD, Hospital Israelita Albert Einstein
  • Surgical Perspectives on Percutaneous Ablation, Pratik Kanabur, MD, UCLA
  • Ablation in Patients with Chronic Renal Disease, Christos Georgiades, MD, PhD, Johns Hopkins University
  • Central Renal Cancer and Ablation in Difficult Locations, Grant Schmit, MD, Mayo Clinic
  • T1B Disease: What is the Current Role of IR? AJ Gunn, MD, University of Alabama at Birmingham

Sarcoma/Desmoids

Moderators: Afshin Gangi, MD, PhD, University Hospital of Strasbourg/NHC; Jack Jennings, MD, PhD, Washington University St. Louis

  • Pivotal Trials and NCCN Guideline Updates, Sean M. Tutton, MD, FSIR, FCIRSE, UCSD Health
  • MDT Care for Desmoids, Bernd Kasper, MD, PhD, University of Heidelberg/Mannheim University Medical Center
  • Cryoablation for Desmoid Tumors, Afshin Gangi, MD, PhD, University Hospital of Strasbourg/NHC
  • Treatment of Primary and Metastatic Sarcoma, Jack Jennings, MD, PhD, Washington University St. Louis
12:45 p.m. - 2:15 p.m.

Y90 Dosimetry Hands-on

The session will begin with an overview provided by expert faculty. Following this introduction, participants will work in pairs at dedicated work stations to calculate and prescribe doses for prepared mock cases of varying difficulty using multiple models and under the supervision of faculty.

  • Nima Kokabi, MD, UNC Chapel Hill
  • Shamar Young, MD University of Arizona
  • Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center
  • Zach Berman, MD, UC San Diego
  • Tyler Sandow, MD, Ochsner Health

Pre-registration is required to secure a dedicated workstation, at no additional fee. Additional space will be available for observers based on room capacity.
2:30 p.m. - 3:30 p.m.

mCRC

Moderators: Martijn Meijerink, MD, PhD, Amsterdam UMC; Yuman Fong, MD, PhD, City of Hope Medical Center

  • Current Landscape of Colorectal Disease, Kimberly Perez, MD, Dana-Farber Cancer Institute/Harvard Medical School
  • Overview of Surgical Strategies and Trends in Management of Colorectal Mets, Laleh Melstrom, MD, MSCI, City of Hope
  • Synergy with Systemic and Locoregional Therapies: Expanding the Curative Role, Martijn Meijerink, MD, PhD, Amsterdam UMC
  • Embolic Treatment and Radiation Segmentectomy, Guy Johnson, MD, PharmD, University of Washington
  • Optimizing the Liver for Surgical Resection, José Hugo Mendes Luz, MD, INCA National Cancer Institute of Brazil

Must-Know Studies for MDT Tumor Board

Moderators: Phillipe Pereira, MD, SLK Kliniken GmbH Heilbronn; Rony Avritscher, MD, University of Texas MD Anderson Cancer Center; Terence P. Gade, MD, PhD, University of Pennsylvania

  • The Importance of Trials and Registries in Interventional Oncology, Phillipe Pereira, MD, SLK Kliniken GmbH Heilbronn
  • ACCLAIM, Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE, Memorial Sloan Kettering Cancer Center
  • IMbrave150, Adam Burgoyne, MD, PhD, UC San Diego
  • LAUNCH, Lynn Jeanette Savic, MD, Universitätsmedizin Charité Berlin
  • Dosisphere, S. Cheenu Kappadath, PhD, FAAPM, University of Texas MD Anderson Cancer Center

Y90 Resin

Moderators: Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center; Irene Bergellini, MD, Candiolo Cancer Institute

  • Updates in Dosimetry with Resin Microspheres Using Pre-Calibration Vials, Marnix Lam, MD, PhD, University Medical Center Utrecht
  • Radiation Segmentectomy with Resin Microspheres, Nima Kokabi, MD, UNC Chapel Hill
  • Updates from the RESIN Registry, John D. Louie, MD, Stanford University
  • Resin Radioembolization for Cholangiocarcinoma, Irene Bergellini, MD, Candiolo Cancer Institute
  • Challenging Clinical Scenarios in Advanced Resin Radioembolization, Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center
3:30 p.m. - 5:00 p.m.

Expo Hall and Discovery Theatre

  • Discovery Theatre presented by Varian, a Siemens Healthineers Company
  • 2024 Young IO Research Fellowship Awardee Presentations, Ornela Sulejmani, Charité Universitätsmedizin; Sara Abosabie, Yale School of Medicine
  • Talk Tuesdays@SIO “Clinical and translational study design” pt.1
    • Anatomy of a clinical trial – observational and interventional studies, Michael Soulen, MD, University of Pennsylvania
    • Statistical concepts and Fundamentals of Phase 1, 2, and 3 clinical trials, William Rilling, MD, FSIR, Medical College of Wisconsin
    • Translate evidence into guideline recommendations, Amy Deipolyi, MD, PhD, Charleston Area Cancer Center
5:00 p.m. - 6:00 p.m.

mCRC Tumor Board

Moderators: Constantinos T. Sofocleous, MD, PhD, FSIR, FCIRSE, Memorial Sloan Kettering Cancer Center; Martijn Meijerink, MD, PhD, Amsterdam UMC

Faculty: Guy Johnson, MD, PharmD, University of Washington; Laleh Melstrom, MD, MSCI, City of Hope; Heather McGee, MD, PhD, City of Hope Medical Group; Kimberly Perez, MD, Dana-Farber Cancer Institute/Harvard Medical School

  
5:30 p.m. - 6:15 p.m.

Industry Member Reception

Invite only, more details to come.
8:30 p.m. - 10:30 p.m.

SIO Trivia Night 2024: Tinseltown Trivia

Join us in the Seaview Ballroom at the Hyatt Regency Long Beach to show off your trivia skills! 

table border="0" cellpadding="0" cellspacing="0" class="colored"> Sunday, 28 January 2024 7:45 a.m. - 8:30 a.m.

Breakfast and CME Session: Optimal Preparation and Treatment Endpoints in cTACE

Breakfast will be provided. Following the overview, participants will engage in hands-on learning at workstations supervised by expert faculty.

  • Overview, Sarah White, MD, MS, Medical College of Wisconsin
  • William Rilling, MD, FSIR, Medical College of Wisconsin
  • Michael Soulen, MD, University of Pennsylvania
  • Nicholas Fidelman, MD, University of California San Francisco
  • Terence P. Gade, MD, PhD, University of Pennsylvania
  • Nadine Abi-Jaoudeh, MD, UC Irvine
  • Juan Gimenez, MD, Ochsner Health
  • Tyler Sandow, MD Ochsner Health

8:45 a.m. - 10:15 a.m.

IO Essentials: Preparing for Tumor Boards

Moderators: Stephen Hunt, MTR, MD, PhD, FSIR, University of Pennsylvania; Nadine Abi-Jaoudeh, MD, UC Irvine

  • BCLC Immunotherapy: Current Status and Outcomes, Cristal Brown, MD, MHS, UT Austin Dell Medical School
  • Liver Transplantation: Patient Selection, Anatomy, and Outcomes, Jennifer Berumen, MD, UC San Diego
  • Tumor Board, All above faculty; Dimitrios Filippiadis, MD, PhD, MSc, EBIR, University General Hospital Attikon; Nishita Kothary, MD, FSIR, Stanford School of Medicine

9:00 a.m. - 10:00 a.m.

Intermediate Stage HCC

Moderators: Edward Kim, MD, FSIR, Mount Sinai Health Systems; Sarah White, MD, MS, Medical College of Wisconsin

  • Curative Options in Early Stage HCC, Roberto Iezzi, MD, Fondazione Pol Gemelli IRCCS Catholic University
  • Combining Locoregional and Systemic Thearpy: What, When, and Where, Ronald S. Arellano, MD, Massachusetts General Hospital
  • Downstaging Strategies, Franco Orsi, MD, EBIR, FCIRSE, European Institute of Oncology (IRCCS)
  • TACE vs. Y90 in Intermediate HCC, Sarah White, MD, MS, Medical College of Wisconsin
  • Sequencing Multiple Therapies, Sammy Saab, MD, UCLA

10:30 a.m.- 11:30 a.m.

Scientific Oral Abstracts

Moderators: Ncholas Fidelman, MD, University of California San Francisco; Rony Avrischer, MD, University of Texas MD Anderson Cancer Center

  • Cone-beam Computed Tomography Guided Percutaneous Cryoablation of Bone Metastases due to Endocrine Tumors: A prospective clinical trial, Ricardo Miguel Costa de Freitas, MD, PhD, Instituto do Cancer do Estao de Sao Paulo (HCFMUSP)
  • Deep Convolutional-neural-network-based Metal Artifact Reduction for CT-guided Interventional Oncology Procedures (MARIO), Wenchao Cao, Mayo Clinic
  • Pharmacokinetic comparison of percutaneously injected ultrasound and x-ray imageable thermosensitive poloxamer-based hydrogel containing doxorubicin versus free drug in swine, Jose F. Delgado, BS, National Institutes of Health
  • Heterogeneity of Hepatocellular Carcinoma (HCC) Response to Y-90 Microsphere Treatment Revealed through in vitro Screening of Patient-Derived Tumoroids and Cell Lines, Christopher Malone, MD, Washington University School of Medicine
  • Histopathologic Analysis of Time-dependent PD-1/PD-L1 expression after TACE in an Orthotopic HCC Model, Ajay Varadhan, Northwestern Memorial Hospital
  • Shapeable temporary hydrodissection gel for thermal protection during liver lesion ablation., Avik Som, MD, PhD, Massachusetts General Hospital
  • CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC, Lukas Salvermoser, MD, University Hospital Munich Germany

11:30 a.m. - 12:45 p.m.

Expo Hall Open

 

Lunch and Industry Symposium presented by Stryker

Radiofrequency Ablation for Vertebral Tumors

  • Jay Acharya, MD, Keck Medicine of USC

 

Lunch and Industry Symposium presented by AstraZeneca

Treatment Option for Unresectable Hepatocellular Carcinoma

  • Mohammed Najeeb Al-Hallak, MD, Karmanos Cancer Institute

12:45 p.m. - 1:45 p.m.

Prostate/GU

Moderators: David Woodrum, MD, PhD, Mayo Clinic; Erica Knavel Koepsel, MD, University of Wisconsin Madison

  • Prostate Cancer Recurrence and CT-Guided Prostate Interventions, Vijay Ramalingam, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
  • Intro to Critical Anatomy in Prostate Ablation, David Woodrum, MD, PhD, Mayo Clinic
  • Energy Modalities for Focal Prostate Cancer Treatment, Eric M. Walser, MD, FACR, The University of Texas Medical Branch
  • MRI-Guided Prostate Interventions, Erica Knavel Koepsel, MD, University of Wisconsin Madison

12:45 p.m. - 2:15 p.m.

Y90 Dosimetry Hands-on

The session will begin with an overview provided by expert faculty. Following this introduction, participants will work in pairs at dedicated work stations to calculate and prescribe doses for prepared mock cases of varying difficulty using multiple models and under the supervision of faculty.

  • Nima Kokabi, MD, UNC Chapel Hill
  • Shamar Young, MD University of Arizona
  • Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center
  • Zach Berman, MD, UC San Diego
  • Tyler Sandow, MD, Ochsner Health

Pre-registration is required to secure a dedicated workstation, at no additional fee. Additional space will be available for observers based on room capacity.

MSK Basic to Advanced

Moderators: Afshin Gangi, MD, PhD, University Hospital of Strasbourg/NHC; Jack Jennings, MD, PhD, Washington University St. Louis

  • Imaging and Biopsy of Bone and Soft Tissue Lesions, Jack Jennings, MD, PhD, Washington University St. Louis
  • Cement and Screws, Steven Yevich, MD, MPH, MD Anderson Cancer Center
  • Cement Augmentation and Osteosynthesis in the Treatment of Painful Bone Metastases, Brandon M. Key, MD, Medical College of Wisconsin
  • Basics of Spine Ablation and Role of Combination Therapy, Anderanik Tomasian, MD, University of Southern California
  • Neuromonitoring and Thermoprotective Techniques, Resten Imaoka, MD, Washington University
  • Ablation and Combined Radiation and Ablation Therapy for Extra-Spinal Lesions, Anil Nicholas Kurup, MD, Mayo Clinic
  • Complications of MSK Ablation, Alexis Kelekis, MD, PhD, EBIR, National and Kapodistrian University of Athens

2:30 p.m. - 3:30 p.m.

Interventional Oncology and Immunotherapy

Moderators: Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center; Terence P. Gade, MD, PhD, University of Pennsylvania

  • General Overview: Where Are We Currently? Gosse J. Adema, PhD, Radboud University Medical Center
  • Immunotherapy and Percutaneous Ablation: What's New and Where Are We Going? Michal Mauda-Havakuk, MD, PhD, Tel-Aviv Sourasky Medical Center
  • Immunotherapy and Intra-Arterial Therapy: What's New and Where Are We Going? Rony Avritscher, MD, University of Texas MD Anderson Cancer Center
  • Positive Effects of Local Therapies, Prof. S. Nahum Goldberg, MD, FSIR, FCIRSE, Hadassah Hebrew University Medical Center

Head and Neck Cancers

Moderators: Uei Pua, MBBS, FRCR, Mmed, FAMS, FSIR, FCIRSE, FAAC, Tan Tock Seng Hospital; Kazim H. Narsinh, MD, UCSF

  • Interventions for Head and Neck Cancers, Uei Pua, MBBS, FRCR, Mmed, FAMS, FSIR, FCIRSE, FAAC, Tan Tock Seng Hospital
  • Intra-Arterial Therapies for Head and Neck Tumors, Stephen Chen, MD, UT MD Anderson Cancer Center
  • Ablation for Primary and Metastatic Thyroid Cancer, Franco Orsi, MD, EBIR, FCIRSE, European Institute of Oncology (IRCCS)
  • Emergency Intervention in Head and Neck Cancers, Steven W. Hetts, UCSF

Palliative Interventions

Moderators: Dimitrios Filippiadis, MD, PhD, MSc, EBIR, University General Hospital Attikon; Marwan Moussa, MD, Beth Israel Deaconess Medical Center/Harvard Medical School

  • Image-Guided Injections, Dimitrios Filippiadis, MD, PhD, MSc, EBIR, University General Hospital Attikon
  • Nerve Cryoablation: Approaches and Techniques, Marwan Moussa, MD, Beth Israel Deaconess Medical Center/Harvard Medical School
  • Palliative Venous Interventions, Dong Il Gwon, MD, PhD, University of Ulsan College of Medicine/Asan Medical Center
  • Pancreatic IRE: Palliative or Ready for Prime Time? Raj Narayanan, MD, Miami Cancer Institute/Baptist Health SF

3:30 p.m. - 5:00 p.m.

Expo Hall and Discovery Theatre

  • Discovery Theatre Poster Presentations
    • Efficacy and safety of percutaneous computed tomography-guided lung biopsies using a table-mounted robotic system: a bi-central study, Anastasia Karachaliou, Attikon University Hosiptal, Athens
    • Assessment of Technical and Clincal Factors in the Utilization of Percutaneous Electromagnetic Navigation System for Computed Tomography-Guided Liver Microwave Ablation, Ornella Moschovaki-Zeiger, MD, PhD Attikon University Hospital, Athens
    • The Oncopig hepatocellular carcinoma model as a tool for locoregional therapeutic studies, Kyle Schachtschneider, PhD, University of Illinois at Chicago
  • Talk Tuesdays@SIO “Clinical and translational study design” pt.2
    • How to write a specific aims page? – approaches for an investigator-initiated study,  Julius Chapiro, MD, Yale University
    • Translational Research 101: Biomarkers and correlative studies, Terence Gade, MD, PhD, University of Pennsylvania
    • Funding & support tools for research and clinical trials, Brad Wood, MD, NIH

5:00 p.m. - 6:00 p.m.

Oligomets Tumor Board

Moderators: David Breen, MD, MRCP, FRCR, University Hospitals Southampton; Matthew Callstrom, MD, PhD, Mayo Clinic

Faculty: Alexis Kelekis, MD, PhD, EBIR, National and Kapodistrian University of Athens; Jess Maxwell, MD, MBA, MD Anderson Cancer Center; Ann Radlow, MD, MPH, UCLA Dept. of Radiation Oncology; Sandy Liu, MD, City of Hope

7:00 p.m. - 10:00 p.m.

Sunday Soiree*

BO beau kitchen + rooftap, first floor

* Sunday Soiree attendance requires an additional fee.